Oral Iron chelation therapy with Deferiprone in patients with Thalassemia Major

Journal of the Pakistan Medical Association

Volumn 59, Issue 6, 2009, Pages 388-390

  Sajid, Raihan ^a   Ghani, Farooq ^a   Adil, Salman ^a   Khurshid, Mohammad ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; BLOOD TRANSFUSION; BONE PAIN; CHELATION THERAPY; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SWELLING; THALASSEMIA MAJOR; TREATMENT OUTCOME; VOMITING; BETA-THALASSEMIA; PAKISTAN; PRESCHOOL CHILD; QUESTIONNAIRE; YOUNG ADULT;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; PAKISTAN; PROSPECTIVE STUDIES; PYRIDONES; QUESTIONNAIRES; YOUNG ADULT;

EID: 66949116353     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ahmed S, Petrou M, Saleem M. Molecular genetics of beta thallasaemia in Pakistan: a basis for prenatal diagnosis. Br J Haematol 1996; 94: 476-482 (Pubitemid 26284070)
2. Ayyub M, Ali W, Anwar M, Waqar A, Khan MN, Ijaz A et al. Efficacy and adverse effects of oral iron chelator deferiprone (11,1,2-dimethyl-3- hydroxypyrid-4-one) in patients with beta thalassemia major in Pakistan. J Ayub Med Coll Abbotatbad 2005; 17: 12-15
3. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107: 3436-3441
4. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamina, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr 2004; 41: 21-27 (Pubitemid 38139865)
5. Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999; 55: 1-6. (Pubitemid 29144092)
6. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006; 85: 315-319 (Pubitemid 43732654)
7. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of Long term therapy with the oral iron chelator Deferiprone. Blood 2003; 102: 1583-1587 (Pubitemid 37022545)
8. Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007; 3: CD 004839. (Pubitemid 351805588)